Following FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application (NDA), the company has today announced a significant reorganisation. The overhaul sees around 75% of the company’s workforce laid off, with the remaining skeleton team focused on “ongoing clinical development, medical affairs, and engagement with the FDA.” As the company prepared for a…
